An observational study in Alzheimer's Disease and Dementias, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 55 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-04-22.
Sponsored by Duke University · Observational
To establish a cutoff value using a ratio of CSF tau to Aβ42 (tau/Aβ42) for distinguishing patients wth mild to moderate Alzheimer's disease (AD) from health elderly control subjects. The investigators hypothesize that a cutoff can be found that has at least 80% sensitivity and 60% specificity.
This study will enroll 50 AD subjects, 50 normal controls and approximately 20 subjects with non-AD dementia. There will be 2 visits (up to 30 days apart), and a telephone follow-up visit.
This protocol does not include treatment of subjects. Lumbar puncture and phlebotomy are routine clinical tasks and are associated with a low level of risk. All adverse events will be documented and reviewed by the PI.
3,675 studies on the registry are indexed under Alzheimer Disease; 869 are open to participants now.
This study's enrollment of 40 is below the median of 200 across 751 observational studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Duke University is the lead sponsor of 2,025 studies on the registry; 275 are open to participants now.
Of its 194 completed or terminated interventional studies of FDA-regulated products, 159 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Duke Memory Disorders Clinic
Inclusion Criteria:
Additional Inclusion Criteria for Normal Controls:
Additional Inclusion Criteria for AD Subjects:
Must meet the criteria for a diagnosis of probable AD based on both
Must have a clear history of cognitive and functional decline over at least one year that is either
Exclusion Criteria for AD Subjects and Normal Controls
Additional Inclusion and Exclusion Criteria for Subject with non-AD dementias
1. Those with Alzheimer's disease 2. Those with non-Alzheimer's disease dementia 3. Healthy elderly volunteers
Ratio of CSF tau to Aβ42 (tau/Aβ42)
CSF will be collected in clinic and shipped frozen to Merck's Clinical Development Lab for testing. Any remaining samples will be kept up to 20 years.
Time frame: CSF will be collected at Visit 1 (up to 30 days after the screening visit)
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Duke University